EIKN

Eikon Therapeutics

• Seeking Alpha·5d ago

  Largest IPOs of the last 90 days register mixed debut

• Benzinga·03/31 14:18

  Wedbush Reiterates Underperform on Eikon Therapeutics, Maintains $7 Price Target

• TipRanks·03/31 13:56

  J.P. Morgan Sticks to Their Buy Rating for Eikon Therapeutics, Inc. (EIKN)

• TipRanks·03/31 12:24

  Eikon Therapeutics, Inc. (EIKN) Gets a Sell from Wedbush

• Seeking Alpha·03/30 13:19

  Eikon Therapeutics GAAP EPS of -$115.29

• Reuters·03/30 11:55

  Eikon FY25 net loss widens 37% to $333.6 million

• Dow Jones·03/30 11:50

  *Eikon Completed Enrollment of TeLuRide-005 Phase 2 Trial of EIK1001 in First-Line Treatment of Stage 4 Non-Small Cell Lung Cancer >EIKN

• Dow Jones·03/30 11:49

  *Eikon Therapeutics 4Q Loss $79.7M >EIKN

• Dow Jones·03/30 11:48

  Press Release: Eikon Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Clinical and Corporate Updates

• Dow Jones·03/30 11:48

  Press Release: Eikon Therapeutics Announces -2-

• TipRanks·03/03 15:20

  Analysts Are Bullish on These NA Stocks: BitGo Holdings, Inc. Class A (BTGO), Eikon Therapeutics, Inc. (EIKN)

• Benzinga·03/02 18:49

  Cantor Fitzgerald Initiates Coverage On Eikon Therapeutics with Overweight Rating

• Reuters·03/02 18:09

  BUZZ-Perlmutter-backed Eikon Therapeutics rises as IPO research quiet period ends 

• TipRanks·03/02 16:30

  Opening Day: Generate Biomedicines makes public debut

• TipRanks·03/02 13:58

  Eikon Therapeutics initiated with an Overweight at Cantor Fitzgerald